Purpose of review Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent or persistent symptomatic infection of the nails, skin and mucosae mostly by Candida albicans. CMC is common in patients with profound primary T-cell immunodeficiency, who often display multiple infectious and autoimmune diseases. Patients with syndromic CMC, including autosomal dominant hyper IgE syndrome (AD-HIES) and autosomal recessive autoimmune polyendocrinopathy syndrome type I (APS-I), display fewer other infections. Patients with isolated CMC (CMCD) rarely display any other severe disease. We review here recent progress in the genetic dissection of these three types of inherited CMC.
INTRODUCTION
Chronic mucocutaneous candidiasis (CMC) is characterized by recurrent or persistent symptomatic mucocutaneous infections caused by fungi of the genus Candida, mostly the commensal Candida albicans, affecting the nails, skin, and oral and genital mucosae [1] [2] [3] [4] [5] . CMC is frequent in newborns and children [6] and is also common in patients with broad and profound quantitative or qualitative, acquired or inherited T-cell deficiencies, in whom it manifests principally as severe recurrent oral candidiasis [7-9,10 && ]. Severe oropharyngeal candidiasis remains common in HIV-infected patients and was the most frequent opportunistic fungal infection in these patients before the introduction of effective antiretroviral treatments [7, 11] . It is also seen in patients on immunosuppressive, antibiotic, or steroid treatments [1] . Patients with primary immunodeficiencies (PIDs) affecting T cells, including severe combined immunodeficiency (SCID) [12] and combined immunodeficiencies (CIDs) [12, 13] , are also prone to CMC. However, in these PIDs, CMC is only one of the many infections to which patients are susceptible and there may also be other clinical signs, such as autoimmunity. By contrast, CMC is the principal or only infectious disease frequently observed in patients with autosomal dominant hyper IgE syndrome (AD-HIES) who also display severe skin and pulmonary staphylococcal disease bearing dominant negative mutations of the STAT3 transcription factor gene [14] and in patients with autosomal recessive autoimmune polyendocrinopathy syndrome type I (APS-I) due to AIRE mutations, who are not susceptible to any other infectious disease [3] . Finally, CMC has been reported together with dermatophytosis and Candida meningitis in the only family with CARD9 deficiency identified to date [15] . We will refer to these three conditions as 'syndromic CMC' below.
Some patients with CMC have no other prominent, overt clinical manifestations [1, 2, 4] . This rare condition (about 1/100 000 individuals) is often referred to as CMC disease [CMCD; Online Mendelian Inheritance in Man (OMIM) 114580, 607644, 212050, 613953, 613956]. The first sporadic cases were described in the 1960s and the first familial cases, typically with segregation as an autosomal dominant trait or, more rarely, as an autosomal recessive trait in some consanguineous families, were reported in the 1970s [16] [17] [18] [19] . Over the next 40 years, other sporadic and familial cases were reported [15, [15, 34] , dermatophytosis [25, 26] , bacterial infections of the respiratory tract and staphylococcal diseases of the skin [32, 33, 61] have been reported in a few patients. In addition, some patients with CMCD display thyroid autoimmunity [2,22,27,35,38, [18, 22, [70] [71] [72] [73] [74] but, from the 1980s onwards, with the advent of antifungal agents, research into CMCD declined, probably accounting for the paradoxical lack of published studies on the clinical features of patients with CMCD. We review here recent progress in the genetic dissection of the primary T-cell deficiencies underlying CMC, syndromic CMC and CMCD.
CHRONIC MUCOCUTANEOUS CANDIDIASIS ASSOCIATED WITH PRIMARY T-CELL IMMUNODEFICIENCIES
Patients with SCID lack autologous T cells and are highly vulnerable to a broad range of microorganisms, including C. albicans in particular. Indeed, severe oropharyngeal candidiasis is common in these patients [8,9,10 && ,12,63] . Patients with CIDs and impaired T-cell development and/or function are also often prone to CMC, although they generally also develop other often more severe infectious diseases [12] . CMC has been reported in patients with autosomal recessive CD25 deficiency, who have low T-cell counts and are highly susceptible to viral and bacterial diseases, persistent oral thrush and Candida oesophagitis [75, 76] . It has also been found in patients with X-linked recessive NF-kB essential modulator (NEMO) disorders or autosomal dominant IkBa disorders, both of which result in a complex PID conferring susceptibility to invasive encapsulated pyogenic bacterial and environmental mycobacterial infections, in particular [77] . CMC has also been reported in patients with autosomal recessive DOCK8 deficiency, a severe CID associated with recurrent viral and bacterial infections [78, 79] , impaired T-cell activation and low IL-17-producing T-cell counts [80, 81] and in patients with autosomal recessive TYK2 deficiency, which is associated with susceptibility to viral, intracellular and extracellular bacterial diseases [82] . Patients with autosomal recessive TCR-a deficiency, which is associated with susceptibility to viral and bacterial diseases, have also been reported to display CMC [83] , and CMC has also been described in patients with autosomal recessive ORAI1 deficiency, which is associated with severe viral, bacterial,
KEY POINTS
The article provides an overview on the recent molecular dissection of various primary immunodeficiencies with chronic mucocutaneous candidiasis (CMC) and of isolated CMC (CMCD).
Altogether these studies have demonstrated the essential role played by human IL-17-mediated immunity in mucocutaneous protection against Candida albicans and to a lesser extent against Staphylococcus aureus in natura.
The further genetic and immunological dissection of the pathogenesis of CMCD should delineate the function of various genes controlling IL-17 immunity, of genes only remotely involved in the IL-17 circuit, of genes not previously connected with IL-17, and even of genes governing circuits unrelated to IL-17.
mycobacterial and fungal infections [84] ; in patients with autosomal recessive MST1 deficiency, which is associated with recurrent bacterial and viral infections [85] (Crequer A, manuscript in preparation) and in patients with autosomal recessive IRF8 deficiency, most of whom present severe mycobacterial disease [86] . Finally, CMC has been documented in more complex T-cell disorders [13] . By contrast, PIDs not affecting T-cell number and/or function, such as those affecting mostly B cells, phagocytes or complement, are not usually associated with CMC [13, 87] . These findings demonstrate the essential role of human T cells in mucocutaneous immunity to C. albicans.
SYNDROMIC CHRONIC MUCOCUTANEOUS CANDIDIASIS
Chronic mucocutaneous candidiasis is one of the two main infectious diseases affecting patients with AD-HIES, bearing mutations in STAT3, the other being recurrent staphylococcal disease of the skin and lungs [14, 88] . These patients have very small proportions of IL-17 and IL-22-secreting T cells, probably due to impaired STAT3-dependent signalling downstream from IL-6, IL-21 and/or IL-23 ( Fig. 1) [89] [90] [91] [92] [93] , which have been shown to be essential for the differentiation or maintenance of Th17 cells in mice [94] . An albeit smaller decrease in the proportion of IL-17 T cells was also observed in patients with autosomal recessive IL-12p40 or IL-12Rb1 deficiency, who suffer from Mendelian susceptibility to mycobacterial disease (MSMD) and, to a lesser extent, mild CMC, probably due to impaired IL-23 signalling [91, 95, 96] (Rodríguez-Gallego C, manuscript in preparation). A small proportion of IL-17-producing T cells was also found in the only kindred with autosomal recessive CARD9 deficiency reported to date, some of the members of which presented CMC, superficial skin dermatophytosis and invasive candidiasis (meningitis) [15] . As only one CARD9-deficient kindred has been reported, it would be premature to draw firm conclusions about the possible dependence of IL-17-producing T-cell development on CARD9. However, CARD9 is an adaptor that acts downstream from various receptors, including Dectin-1, Dectin-2, mannose receptor, and macrophage-inducible C-type lectin (MINCLE), which can recognize C. albicans (Fig. 1) [97] . The observed IL-17-producing T-cell deficiency may thus result from defects in the production of cytokines promoting IL-17-producing T-cell development or maintenance upon fungal recognition [98, 99] . Isolated CMC with an unclear mode of inheritance was reported in a family bearing the Y238X mutation of the Dectin1 gene with apparent impairment of IL-17 production [52] . However, this variation is too frequent (7% in Europeans and up to 40% in the South Africa San population) to be considered disease-causing in autosomal recessive, autosomal dominant or codominance models. Finally, high levels of neutralizing autoantibodies directed against IL-17A, IL-17F and/or IL-22 have been found in the plasma of patients suffering from autosomal recessive APS-I, in which CMC is the only major infection (Fig. 1) [100,101,102 & ]. Together, these findings strongly suggest that impaired IL-17 immunity may underlie CMC (Fig. 1) (Fig. 1) . However, no genetic cause has yet been identified for a number of patients with CMCD.
CONCLUSION
It is almost 40 years since it was first suggested that CMCD was a PID, but the first three genetic causes of this disease were not identified until last year.
These experiments of Nature demonstrate the essential role of IL-17A and IL-17F in protective mucocutaneous immunity to C. albicans and, to a lesser extent, S. aureus in the nails, skin and oral and genital mucosae. These cytokines appear to be otherwise redundant in host defence against other common pathogens. However, description of the precise clinical features of a larger number of patients with inborn errors of IL-17 immunity is required, to determine the role of these cytokines with a greater degree of certainty. We will need to identify more patients with inborn errors of IL-17RA, IL-17F or GOF mutations in STAT1 or other as yet unknown genetic disorders affecting IL-17 immunity to draw definitive conclusions concerning the impact of these genetic lesions on susceptibility to infection. Nevertheless, the studies [124] [125] [126] [127] [128] [129] carried out to date have already provided invaluable insight into the role of human IL-17 immunity in host defence in natura. They also suggest that the pathogenesis of CMC in settings other than CMCD, whether in inherited disorders or in acquired immunodeficiencies, such as AIDS, probably involves impaired IL-17 immunity. In this study, the authors identify first two genetic causes of CMCD: AR IL-17RA and AD IL-17F deficiencies, thereby demonstrating an essential role of human IL-17A and/or IL-17F in mucocutaneous immunity to C. albicans in natura. 106.
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